Rivaroxaban protects from the oxysterol-induced damage and inflammatory activation of the vascular endothelium.
25-hydroxycholesterol
Rivaroxaban
barrier function
inflammatory markers
vascular endothelial damage
Journal
Tissue barriers
ISSN: 2168-8370
Titre abrégé: Tissue Barriers
Pays: United States
ID NLM: 101601065
Informations de publication
Date de publication:
02 Oct 2021
02 Oct 2021
Historique:
pubmed:
30
7
2021
medline:
25
3
2022
entrez:
29
7
2021
Statut:
ppublish
Résumé
Rivaroxaban is one of the direct factor Xa inhibitors. Its function in the inactivated coagulation cascade is unclear. The aim of the study was to assess the effect of rivaroxaban on the endothelial integrity and inflammatory properties of endothelial cells stimulated by 25-hydroxycholesterol (25-OHC). HUVECs were stimulated with 25-OHC, rivaroxaban and 25-OHC+ rivaroxaban. HUVEC integrity and permeability were measured using the xCELLigence system and paracellular flux assay. The mRNA expression of tissue factor, ICAM-1, VEGF, IL-33, MCP-1, TNF-α was analyzed in the real-time PCR. Apoptosis and viability were measured by flow cytometry. The VEGF protein concentration was assessed by ELISA. The confocal microscope was used to evaluate the expression of VE-cadherin in endothelial cells. 25-OHC decreased endothelial cell integrity and increased the mRNA expression of IL-33, tissue factor, ICAM-1, MCP-1, VEGF, TNF-α as compared to unstimulated controls. Following the stimulation with rivaroxaban, HUVEC restored integrity disrupted by 25-OHC ( Our finding suggests that rivaroxaban may restore the endothelial barrier and inhibit the inflammatory activation caused by oxysterol
Sections du résumé
BACKGROUND
BACKGROUND
Rivaroxaban is one of the direct factor Xa inhibitors. Its function in the inactivated coagulation cascade is unclear. The aim of the study was to assess the effect of rivaroxaban on the endothelial integrity and inflammatory properties of endothelial cells stimulated by 25-hydroxycholesterol (25-OHC).
METHODS
METHODS
HUVECs were stimulated with 25-OHC, rivaroxaban and 25-OHC+ rivaroxaban. HUVEC integrity and permeability were measured using the xCELLigence system and paracellular flux assay. The mRNA expression of tissue factor, ICAM-1, VEGF, IL-33, MCP-1, TNF-α was analyzed in the real-time PCR. Apoptosis and viability were measured by flow cytometry. The VEGF protein concentration was assessed by ELISA. The confocal microscope was used to evaluate the expression of VE-cadherin in endothelial cells.
RESULTS
RESULTS
25-OHC decreased endothelial cell integrity and increased the mRNA expression of IL-33, tissue factor, ICAM-1, MCP-1, VEGF, TNF-α as compared to unstimulated controls. Following the stimulation with rivaroxaban, HUVEC restored integrity disrupted by 25-OHC (
CONCLUSION
CONCLUSIONS
Our finding suggests that rivaroxaban may restore the endothelial barrier and inhibit the inflammatory activation caused by oxysterol
Identifiants
pubmed: 34323663
doi: 10.1080/21688370.2021.1956284
pmc: PMC8794498
doi:
Substances chimiques
Oxysterols
0
Rivaroxaban
9NDF7JZ4M3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1956284Références
Br J Clin Pharmacol. 2018 Feb;84(2):280-291
pubmed: 28940408
Cold Spring Harb Perspect Med. 2012 Oct 01;2(10):
pubmed: 23028127
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019 Apr;31(4):468-473
pubmed: 31109423
Thromb Res. 2016 Jun;142:44-51
pubmed: 27131284
Free Radic Biol Med. 2012 Jan 1;52(1):19-34
pubmed: 22037514
Innate Immun. 2015 Nov;21(8):827-46
pubmed: 26403174
Sci Rep. 2016 May 04;6:25171
pubmed: 27142573
BMC Cardiovasc Disord. 2015 Oct 19;15:130
pubmed: 26481314
Redox Biol. 2017 Oct;13:581-587
pubmed: 28783588
Expert Rev Clin Pharmacol. 2019 Aug;12(8):771-780
pubmed: 31269825
Am J Physiol Endocrinol Metab. 2016 Oct 1;311(4):E781-E790
pubmed: 27600825
Brain Res. 2019 Sep 15;1719:57-63
pubmed: 31121158
Tissue Barriers. 2015 Apr 03;3(1-2):e985954
pubmed: 25838987
Am J Health Syst Pharm. 2008 Aug 15;65(16):1520-9
pubmed: 18693206
Circulation. 2020 Jul 7;142(1):40-48
pubmed: 32436455
Atherosclerosis. 2015 Oct;242(2):639-46
pubmed: 25817329
J Atheroscler Thromb. 2020 Aug 1;27(8):809-907
pubmed: 32624554
Eur Heart J. 2018 Mar 1;39(9):758-761
pubmed: 29244065
Inflamm Res. 2013 Dec;62(12):1015-23
pubmed: 24077843
Thromb J. 2003 Oct 11;1(1):6
pubmed: 14613528
Atherosclerosis. 2020 Sep;309:16-26
pubmed: 32858395
J Interferon Cytokine Res. 2009 Jun;29(6):313-26
pubmed: 19441883
J Pharmacol Sci. 2017 Mar;133(3):156-161
pubmed: 28314697
PLoS One. 2020 Dec 10;15(12):e0240669
pubmed: 33301454
Int J Mol Sci. 2020 Mar 13;21(6):
pubmed: 32182973
Arterioscler Thromb Vasc Biol. 2000 Nov;20(11):E107-12
pubmed: 11073863
Mol Biol Cell. 2010 Feb 15;21(4):584-96
pubmed: 20032304
Sci Rep. 2016 May 23;6:26554
pubmed: 27212040
Cardiovasc Diabetol. 2015 Jun 16;14:81
pubmed: 26077117
Circ Res. 2016 Feb 19;118(4):620-36
pubmed: 26892962